Last reviewed · How we verify
Bortezomib, Melphalan, Prednisone
This combination regimen kills multiple myeloma cells by inhibiting the proteasome (bortezomib), damaging DNA (melphalan), and suppressing immune responses (prednisone).
This combination regimen kills multiple myeloma cells by inhibiting the proteasome (bortezomib), damaging DNA (melphalan), and suppressing immune responses (prednisone). Used for Multiple myeloma (newly diagnosed and relapsed/refractory).
At a glance
| Generic name | Bortezomib, Melphalan, Prednisone |
|---|---|
| Also known as | Boirtezomib, velcade |
| Sponsor | Fondazione EMN Italy Onlus |
| Drug class | Proteasome inhibitor + alkylating agent + corticosteroid combination |
| Target | 20S proteasome (bortezomib); DNA (melphalan); glucocorticoid receptor (prednisone) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Bortezomib is a proteasome inhibitor that prevents degradation of pro-apoptotic proteins, triggering cancer cell death. Melphalan is an alkylating agent that cross-links DNA and causes cell death. Prednisone is a corticosteroid that provides immunosuppression and anti-inflammatory effects. Together, these three agents work synergistically to induce apoptosis in myeloma cells and overcome drug resistance.
Approved indications
- Multiple myeloma (newly diagnosed and relapsed/refractory)
Common side effects
- Peripheral neuropathy
- Thrombocytopenia
- Anemia
- Infection
- Nausea/vomiting
- Diarrhea
- Fatigue
- Hyperglycemia
Key clinical trials
- Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma (PHASE3)
- STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA (PHASE4)
- A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma (PHASE3)
- A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens (PHASE2)
- A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma (PHASE1)
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region) (PHASE3)
- Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone (PHASE2)
- Bortezomib With Melphalan and Prednisone for Multiple Myeloma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |